A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
GlobalData on MSN6d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 18, 2025 / Rancho BioSciences, the premier tech-enabled data science ...
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Nations Financial Group Inc. IA ADV lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 10.3% in ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s shares closed yesterday at $54.98. See what stocks ...
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback